EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)ÄquivalenzstudieMultizentrische Studie

Immunotherapy Using HBV Vaccine Pulsed DCs and Induced T‐Cells Combined Antiviral Drugs in Treatment Naive CHB Patients‐A Multi‐Centre Phase II Study

Yurong Gu iD, Lin Gu, Lubiao Chen, Jing Li, Chunhong Liao, Yanhua Bi, Zexuan Huang, Wei Cai, Jia Wei, Yuehua Huang

Journal of Viral Hepatitis · 2025

DOI: 10.1111/jvh.14045 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Yurong Gu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Antiviral Agents, Dendritic Cells, Hepatitis B Vaccines, Hepatitis B, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Grant Program on Key Infectious Disease, Research and Development Planned Project in Key Areas of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dendritic cells are the most potent antigen‐presenting cells in immune therapeutic approaches for chronic hepatitis B (CHB) infection. Here, we developed a clinical trial to evaluate the efficacy and safety of autologous HBV vaccine‐pulsed DCs and their induced T cells (HPDCT) in CHB patients. This was a randomised, prospective, open‐label, multicentre, superiority study and 309 treatment‐naive CHB patients were divided into HPDCT plus nucleos(t)ide analogues (NAs) group ( n = 84), NAs mono‐therapy group ( n = 82), HPDCT plus Peg‐interferon (Peg‐IFN) group ( n = 69), Peg‐IFN mono‐therapy group ( n = 74). Twelve times of HPDCT vaccinations were given intravenously, and all the patients were followed up for 72 weeks. In total, 1836 HPDCT infusions were administered with no obvious toxicity and side effect although few patients had self‐limited low fever. More patients got HBsAg loss in those receiving HPDCT therapy. Patients of HPDCT plus Peg‐IFN group with HBV DNA < 1 × 10 7 IU/mL at baseline exhibited earlier, stronger and longer lasting of viral response, especially HBV DNA < 20 IU/mL, than those patients of Peg‐IFN mono‐therapy group, from week 24 till week 72 ( p < 0.05). Comparable efficacy was observed between the patients of HPDCT plus NAs group and NAs mono‐therapy groups. In addition, CD25 on CD8 + T cells and HBV‐specific CD8 + T cell increased significantly in patients of HPDCT combined antiviral drugs therapy. HPDCT combined with antiviral drugs was safe and able to enhance T cell immunity. Furthermore, HPDCT combined with Peg‐IFN could provide an incremental benefit to patients with baseline levels of lower HBV DNA. Trial Registration: ClinicalTrials.gov identifier: NCT01935635

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDendritic CellsHepatitis B VaccinesHepatitis B, ChronicImmunotherapyT-LymphocytesAdultFemaleHumansMaleMiddle AgedYoung AdultDNA, ViralHepatitis B Surface AntigensHepatitis B virusPolyethylene GlycolsProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

chronic hepatitis Bdendritic cellsimmunotherapy

Substanzen

Antiviral AgentsDNA, ViralHepatitis B Surface AntigensHepatitis B VaccinesPolyethylene Glycols

Autor:innen und Institutionen

  • Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Department of Infectious Diseases and Hepatology, The Second People's Hospital of Yunnan Province, Kunming, China.

ORCID-Profile: Yurong Gu

Förderung

  • National Grant Program on Key Infectious Disease
  • Research and Development Planned Project in Key Areas of Guangdong Province

Zitieren

APA

Gu, Y., Gu, L., Chen, L., Li, J., Liao, C., Bi, Y., Huang, Z., Cai, W., Wei, J., & Huang, Y. (2025). Immunotherapy Using HBV Vaccine Pulsed DCs and Induced T‐Cells Combined Antiviral Drugs in Treatment Naive CHB Patients‐A Multi‐Centre Phase II Study. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.14045

Vancouver

Gu Y, Gu L, Chen L, Li J, Liao C, Bi Y, et al. Immunotherapy Using HBV Vaccine Pulsed DCs and Induced T‐Cells Combined Antiviral Drugs in Treatment Naive CHB Patients‐A Multi‐Centre Phase II Study. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.14045

BibTeX
@article{Gu2025,
  author = {Gu, Yurong and Gu, Lin and Chen, Lubiao and Li, Jing and Liao, Chunhong and Bi, Yanhua and Huang, Zexuan and Cai, Wei and Wei, Jia and Huang, Yuehua},
  title = {Immunotherapy Using HBV Vaccine Pulsed DCs and Induced T‐Cells Combined Antiviral Drugs in Treatment Naive CHB Patients‐A Multi‐Centre Phase II Study},
  journal = {Journal of Viral Hepatitis},
  year = {2025},
  doi = {10.1111/jvh.14045}
}
Kostenlos starten →